Elicio Therapeutics, Inc. (ELTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert T. Connelly | CEO, President & Director | 943.02k | -- | 1960 |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director | 48.12k | -- | 1947 |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer | 648.6k | -- | 1987 |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 721.09k | -- | 1966 |
| Dr. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | -- | -- | -- |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Strategy & Financial Officer and Treasurer | -- | -- | 1973 |
| Mr. Michael DiVecchia | Senior Vice President of Operations & Human Resources | -- | -- | -- |
| Ms. Megan C. Filoon | General Counsel, Secretary & Compliance Officer | -- | -- | -- |
| Ms. Esther Welkowsky | Senior Vice President of Clinical Development | -- | -- | -- |
| Ms. Joy Seymour | VP & Head of Regulatory Affairs | -- | -- | -- |
Elicio Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 32
Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
May 13, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
Elicio Therapeutics, Inc. Earnings Date